IpsiHand Brain-Computer Interface Therapy Induces Broad Upper Extremity Motor Rehabilitation in Chronic Stroke.
Nabi Rustamov, Lauren Souders, Lauren Sheehan and 2 others
PMID 39345118WHAT IT FOUND
Chronic stroke patients using a brain-computer interface hand device for 12 weeks improved upper limb movement by 8.1 points on the Fugl-Meyer scale.
Gains occurred in both the shoulder and hand, exceeding the threshold for clinical benefit, with no adverse events reported.
Key findings
01Patients improved their Upper Extremity Fugl-Meyer score by a mean of 8.1 points, which is above the minimal clinically important difference of 5.25 points.
02Motor improvements were seen in both proximal (shoulder/elbow) and distal (hand) sections of the Fugl-Meyer assessment.
03The addition of Botox injections did not significantly change the motor recovery outcomes compared to patients who did not receive Botox.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
There was no control group, so natural recovery or placebo effects cannot be ruled out, although the authors argue chronic stroke patients typically plateau. The study had a very high dropout rate: only 26 of the 100 consented patients completed the analysis (due to ineligibility, inability to use the BCI, or withdrawal), which introduces potential selection bias. Assessors were not blinded to the treatment, which could introduce bias in subjective scoring. The sample size was small (n=26) and heterogeneous in terms of baseline severity and time post-stroke.
Declared interests
One author (E.C.L.) owns stock in Neurolutions, the company that manufactures the IpsiHand system. Washington University also owns stock in Neurolutions. The study was supported by U.S. Government non-P.H.S. funding.
The easy way to misread this
Do not interpret the 8.1-point improvement as proof that the device works better than standard care or that it causes recovery. Because there was no control group and assessors were not blinded, some of this gain could be due to natural variation, placebo effect, or assessor bias. The high dropout rate also means the results may only apply to the most motivated or capable patients.